Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti-C2 antibody inhibiting allogeneic but not autologous factor VIII activity.

about

Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti-C2 antibody inhibiting allogeneic but not autologous factor VIII activity.

Item

http://www.wikidata.org/entity/Q45878590

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Mild hemophilia A patient with ...... tologous factor VIII activity.

@en

Mild hemophilia A patient with ...... tologous factor VIII activity.

@nl

type

Item

label

Mild hemophilia A patient with ...... tologous factor VIII activity.

@en

Mild hemophilia A patient with ...... tologous factor VIII activity.

@nl

prefLabel

Mild hemophilia A patient with ...... tologous factor VIII activity.

@en

Mild hemophilia A patient with ...... tologous factor VIII activity.

@nl

P1476

Mild hemophilia A patient with ...... utologous factor VIII activity

@en

P2093

H Wakabayashi

http://www.w3.org/2001/XMLSchema#string

K Nogami

http://www.w3.org/2001/XMLSchema#string

K Ogiwara

http://www.w3.org/2001/XMLSchema#string

M Shima

http://www.w3.org/2001/XMLSchema#string

M Takeyama

http://www.w3.org/2001/XMLSchema#string

P2860

F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis

Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex

A3 domain region 1803-1818 contributes to the stability of activated factor VIII and includes a binding site for activated factor IX

High-resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance.

Activation of factor VIII and mechanisms of cofactor action.

Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation.

Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors.

Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development.

CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A.

Thrombin-catalyzed activation of factor VIII with His substituted for Arg372 at the P1 site

P304

1843-1853

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JTH.13118

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

K Yada

P577

2015-09-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26278069

http://www.w3.org/2001/XMLSchema#string

P921

hemophilia

hemophilia A

Coagulation factor VIII